Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression

Archive ouverte

Antoniou, Panagiotis | Hardouin, Giulia | Martinucci, Pierre | Frati, Giacomo | Felix, Tristan | Chalumeau, Anne | Fontana, Letizia | Martin, Jeanne | Masson, Cecile | Brusson, Megane | Maule, Giulia | Rosello, Marion | Giovannangeli, Carine | Abramowski, Vincent | de Villartay, Jean-Pierre | Concordet, Jean-Paul | del Bene, Filippo | El Nemer, Wassim | Amendola, Mario | Cavazzana, Marina | Cereseto, Anna | Romano, Oriana | Miccio, Annarita

Edité par CCSD ; Nature Publishing Group -

International audience. Sickle cell disease and β-thalassemia affect the production of the adult β-hemoglobin chain. The clinical severity is lessened by mutations that cause fetal γ-globin expression in adult life (i.e., the hereditary persistence of fetal hemoglobin). Mutations clustering ~200 nucleotides upstream of the HBG transcriptional start sites either reduce binding of the LRF repressor or recruit the KLF1 activator. Here, we use base editing to generate a variety of mutations in the −200 region of the HBG promoters, including potent combinations of four to eight γ-globin-inducing mutations. Editing of patient hematopoietic stem/progenitor cells is safe, leads to fetal hemoglobin reactivation and rescues the pathological phenotype. Creation of a KLF1 activator binding site is the most potent strategy – even in long-term repopulating hematopoietic stem/progenitor cells. Compared with a Cas9-nuclease approach, base editing avoids the generation of insertions, deletions and large genomic rearrangements and results in higher γ-globin levels. Our results demonstrate that base editing of HBG promoters is a safe, universal strategy for treating β-hemoglobinopathies.

Suggestions

Du même auteur

Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease

Archive ouverte | Ramadier, Sophie | CCSD

International audience. Sickle cell disease (SCD) is caused by a mutation in the b-globin gene leading to polymerization of the sickle hemoglobin (HbS) and deformation of red blood cells. Autologous transplantation ...

Combination of lentiviral and genome editing technologies for the treatment of sickle cell disease

Archive ouverte | Ramadier, Sophie | CCSD

International audience

Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype

Archive ouverte | Weber, Leslie | CCSD

International audience. Sickle cell disease (SCD) is caused by a single amino acid change in the adult hemoglobin (Hb)  chain that causes Hb polymerization and red blood cell (RBC) sickling. The co-inheritance of m...

Chargement des enrichissements...